 |
|
Intravenous Nicardipine for the Treatment of Severe HypertensionA Double-blind, Placebo-Controlled Multicenter Trial
J. David Wallin, MD;
Eugene Fletcher, MD;
C. Venkata S. Ram, MD;
M. Eileen Cook, MD;
Deanna G. Cheung, MD;
E. Paul MacCarthy, MD;
Raymond Townsend, MD;
Elijah Saunders, MD;
W. Ross Davis, MD;
Herbert G. Langford, MD;
George DeVault, MD;
Walter Flamenbaum, MD;
Gray Ellrodt, MD;
Bruce Hamilton, MD;
Stuart Frank, MD;
William Frishman, MD
Arch Intern Med. 1989;149(12):2662-2669.
Abstract
• A placebo-controlled, double-blind multicenter trial was conducted in 123 patients with severe hypertension to examine the efficacy and safety of intravenously administered nicardipine hydrochloride in controlling blood pressure. Seventy-three patients were initially randomized to receive nicardipine treatment. This group had an initial blood pressure of 213±3/126±2 mm Hg. Sixty-seven patients achieved the therapeutic goal (diastolic blood pressure 95 mm Hg; systolic blood pressure  160 mm Hg). Fifty patients were randomized to receive placebo solution. Blood pressure in these patients was 216±3/125±2 mm Hg. No patient in this group achieved the therapeutic goal during the "blinded" portion of the study. Forty-four of 49 patients who did not respond to placebo administration responded to subsequent treatment with nicardipine. Patients with end-organ damage were included in the study. These included patients with left ventricular hypertrophy, retinopathy, and renal insufficiency. Patients with and without end-organ damage responded equally well to nicardipine treatment. Serious adverse experiences were infrequent, the most common adverse reaction being headache in 24% of the patients studied.
(Arch Intern Med. 1989;149:2662-2669)
Author Affiliations
From the Department of Nephrology, Tulane University Medical School, New Orleans, La (Drs Wallin and Cook); the Pulmonary Division, Veterans Administration Medical Center, Houston, Tex (Dr Fletcher); the Department of Internal Medicine, University of Texas Health Science Center at Dallas (Dr Ram); the Hypertension Center, Veterans Administration Medical Center, Long Beach, Calif (Dr Cheung); the Hypertension Program, University of Cincinnati (Ohio) Medical Center (Dr MacCarthy); the Renal Division, Allegheny General Hospital, Pittsburgh, Pa (Dr Townsend); the Department of Internal Medicine, University of Maryland Hospital, Baltimore (Dr Saunders); the Department of Internal Medicine, University of South Alabama Medical Center, Mobile (Dr Davis); the Endocrine and Hypertension Division, Department of Internal Medicine, University of Mississippi, Jackson (Dr Langford); the Nephrology Section, Department of Internal Medicine, Louisiana State University Medical Center, New Orleans (Dr DeVault); Pharm Evaluation Services, Englewood Cliffs, NJ (Dr Flamembaum); Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif (Dr Ellrodt); Department of Internal Medicine, Veterans Administration Medical Center, Baltimore (Dr Hamilton); the Division of Cardiology, Southern Illinois University School of Medicine, Springfield (Dr Frank); and the Department of Cardiology, Albert Einstein School of Medicine. New York, NY (Dr Frishman).
Footnotes
Accepted for publication July 26, 1989.
Reprint requests to Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112 (Dr Wallin).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pharmacotherapeutic options for the treatment of preeclampsia
McCoy and Baldwin
Am J Health Syst Pharm 2009;66:337-344.
ABSTRACT
| FULL TEXT
Treatment of Perioperative Hypertension in the Ambulatory Plastic Surgery Patient
Higgins
Aesthetic Surgery Journal 1999;19:257-259.
ABSTRACT
| FULL TEXT
Electrocardiographic Changes During Acute Treatment of Hypertensive Emergencies With Sodium Nitroprusside or Fenoldopam
Gretler et al.
Arch Intern Med 1992;152:2445-2448.
ABSTRACT
Immediate Treatment of Severe Hypertension
Options and WEBER
Arch Intern Med 1989;149:2635-2637.
ABSTRACT
|
